1.64k followers • 30 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that were removed from most watchlists by Yahoo Finance Users. This list is generated daily and limited to the top 30 stocks that meet the criteria.
Petroleo Brasileiro S.A. - Petrobras
Truist Financial Corporation
SunTrust Banks, Inc.
TD Ameritrade Holding Corporation
Baker Hughes Company
Trip.com Group Limited
Healthpeak Properties, Inc.
Wheaton Precious Metals Corp.
Jacobs Engineering Group Inc.
Cypress Semiconductor Corporation
Five Below, Inc.
Herbalife Nutrition Ltd.
The Medicines Company
Buckeye Partners, L.P.
Audentes Therapeutics, Inc.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the third quarter. We get to see hedge funds' thoughts towards the market and […]
Biotech has been a great performer since I suggested it as a contrarian play on Oct. 11. In that time, the SPDR S&P Biotech exchange-traded fund (XBI) is up 24%, and the iShares Nasdaq Biotechnology Index (IBB) has advanced 20%, compared with 5.2% for the S&P 500 (SPX) The seven stocks I singled out in that column have done well. “Washington is very focused on impeachment and trade talks,” says Jefferies biotech analyst Michael Yee.
Sometimes, it pays to fold 'em.While many investors gear up for the new year by scouting out lists of the best stocks to buy, there's virtue in pruning, too. Even though it seems counterintuitive to sell into a rip-snorting bull market, you should parcel out time to evaluate your portfolio for stocks to sell as we enter 2020.Why? Three reasons: * Too far, too fast. Let's say you own a stock that has soared far above the market. The position that once was 10% of your portfolio is now 35%. That's a lot to have riding on one stock. You don't have to sell your entire holding, but it might be a good idea to trim it back a bit. In fact, you can tie such a move into charitable giving and dodge that pesky capital-gains tax. * Slowdown ahead. Even if your stock has had a whizbang year, you should review it to see if the enthusiasm was a bit overblown. Some stocks that once had stellar records - we're looking at you, Freddie Mac (FMCC) and GameStop (GME) - weren't able to keep the earnings momentum going. If it looks like your stock's growth might be slowing, you should think about where that money could be working a bit harder. Even great buys become stocks to sell at some point. * Right stock, wrong time. Finally, some companies are just in the wrong place at the wrong time, such as energy: the market's worst sector (by a mile) in 2019. Are there good energy stocks? Absolutely. But sometimes, market factors (such as oil prices) punish even the best firms.No one likes selling stocks. You've probably put a lot of work and worry into researching your stocks and holding on to them. But it's an important part of investing, and some of the best investors are not only good buyers of stock, but good sellers. Here then, are five stocks to sell in 2020. SEE ALSO: 43 Companies Amazon Could Destroy (Including One for a Second Time)
Bristol-Myers Squibb Co's head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday. Biondi joined Bristol-Myers in 2002 and had been in charge of business development, helping the company pursue strategic partnerships and deals, since 2015. Bristol-Myers announced the Celgene acquisition last January and the deal closed on Nov. 28.
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
2020 could see a number of high-profile oil auctions, and where 2019 was a mixed bag in terms of asset assets, this year is shaping up to be more promising
Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.
TD Ameritrade Holding Corp. (NASDAQ: AMTD) clients were net buyers of Walt Disney Co (NYSE: DIS) during November following Disney’s release of its highly anticipated streaming service Disney+. This is according to the TD Ameritrade IMX, a monthly measure of buying and selling activity among the firm’s clients. Shares of Disney hit an all-time high on Nov. 26 after it was reported that the streaming platform was averaging 1 million new subscribers per day.
The U.S. and China may be trying to negotiate an end to their trade war continues, many local businesses have prepared for difficult times by stocking up on inventory. That, along with merger activity and baby boomer legacies are among the trends observed by Truist exec Johnny B. Moore Jr.
The Saudi royal family celebrated, but it is hard for investors to assess the listing. Political incentives and the stock’s small float make it hard to argue this is a natural price.
Brazilian state-run oil firm Petrobras will produce more than 2.7 million barrels of oil equivalent per day (boepd) in 2019, with total production coming in on the upper end of the target range, an executive said on Wednesday. In its formal guidance, Petroleo Brasileiro SA, as the firm is formally known, predicted it would produce 2.7 million boepd in 2019, though actual production could vary 2.5% above or below the target.
Chevron announced its capital spending plans for 2020—and also said it was taking a $10 to $11 billion asset write down, mainly related to natural gas related assets. That could move energy sector stocks in Wednesday trading.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
The speculative property was completed last November and has since been fully leased to five biopharmaceutical/biotech companies.
Buying the right stocks at the right time is key to investing. Check out Splunk, Fortinet, AutoZone, Inphi and Pan American Silver.
Brazil's state-controlled oil company Petrobras SA is mulling construction of a new lubricant plant that could quadruple its production capacity by 2022, the company's refining chief said on Tuesday. Anelise Lara, Petrobras' refining and natural gas chief, told Reuters the company will invest about $400 million to build the new plant in the Comperj refinery, raising its lubricant production capacity to 225,00 cubic meters. When the Comperj plant is concluded, Petrobras plans to shut down its lubricant production unit at Reduc.
A publicly traded discount retail store plans to build its third distribution center nationwide north of Houston.
Analyst Chase Mulvehill put Baker Huges on Bank of America’s “U.S. 1” list—a collection of the bank and brokerage firm’s best ideas. General Electric has more than $8 billion worth of Baker shares.